1. Academic Validation
  2. NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma

NEU4-mediated desialylation enhances the activation of the oncogenic receptors for the dissemination of ovarian carcinoma

  • Oncogene. 2024 Nov;43(49):3556-3569. doi: 10.1038/s41388-024-03187-x.
Jie Shi 1 Rui Zhou 1 Shuo Wang 1 Yuxin Liu 1 Baorui Tian 1 Yanhua Liu 1 Yanan Chen 1 Taoyu Hu 1 Yuhao Mu 1 Shufan Wang 1 Xintao Shao 1 Jie Yan 1 Pengpeng Qu 2 Ding Wei 2 Shuang Yang 1 Yi Shi 3 Jia Li 4 Longlong Wang 5
Affiliations

Affiliations

  • 1 The School of Medicine, Nankai University, Tianjin, China.
  • 2 Department of Gynecological Oncology, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China.
  • 3 The School of Medicine, Nankai University, Tianjin, China. 016008@nankai.edu.cn.
  • 4 The School of Medicine, Nankai University, Tianjin, China. lijia0731@nankai.edu.cn.
  • 5 The School of Medicine, Nankai University, Tianjin, China. wangl@nankai.edu.cn.
Abstract

Glycosylation profoundly influences the interactions between Cancer cells and microenvironmental stromal cells during the peritoneal disseminated metastasis of ovarian carcinoma (OC), which is the major cause of cancer-related death. Although the characteristic Cancer glycoconjugates are widely used as biomarkers for Cancer diagnosis, our knowledge about Cancer glycome remains quite fragmented due to the technique limitations in analyzing glycan chains with tremendous structural and functional heterogeneity. Given the dysregulated Cancer glycome is defined by the altered glycosylation machinery, here we performed a systematic loss-of-function screen on 498 genes involved in glycosylation for key regulators of OC dissemination. We identified neuraminidase 4 (NEU4), an Enzyme capable of hydrolyzing terminal sialic acid from glycoconjugates, as a vital peritoneal dissemination-promoting modifier of OC glycome. In human patients with high-grade serous OC (HGSOC), increased NEU4 was detected in the disseminated OC cells when compared with that in the primary tumor cells, which significantly correlated with the worse survival. Among three alternative splice-generated isoforms of human NEU4, we revealed that only the plasma membrane-localized NEU4 isoform 2 (NEU4-iso2) and intracellular isoform 3 promoted the peritoneal dissemination of OC by enhancing the cell motility and epithelial-mesenchymal transition. We also identified NEU4-iso2-regulated cell surface glycoproteome and found that NEU4-iso2 desialylated the epithelial growth factor receptor (EGFR), in particular at N196 residue, for the hyperactivation of EGFR and its downstream tumor-promoting signaling cascades. Our results provide new insights into how the OC glycome is dysregulated during OC progression and reveal a functionally important glycosite on EGFR for its abnormal activation in Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15772
    99.96%, Mutant-Selective EGFR Inhibitor